Moderna has applied for US and European emergency authorisation of its Covid-19 vaccine on Monday based on full results from a late-stage study showing its vaccine was 94.1% effective with no serious safety concerns. It also reported a 100% success rate in preventing severe cases. The filing sets Moderna's product up to be the second vaccine likely to receive US emergency use authorisation this year. Moderna's announcement follows news from Pfizer Inc and German partner BioNTech SE that their vaccine, which also uses a new technology called synthetic messenger RNA, was 95% effective.
Covid in India: 18,599 new infections push country's tally to 1.12 crore
India is in the endgame of Covid pandemic: Harsh Vardhan
India records 18,711 fresh Covid-19 cases in 24 hours
Trillion dollar push, US Senate gives nod to Covid stimulus bill
Lord's not to host World Test Championship final: report
100-year old woman from Mumbai gets vaccine jab on her birthday
Gujarat man tests Covid+ after taking 2nd dose of vaccine
As Covid cases surge Central teams rushed to Maharashtra, Punjab
Dutch artist's 'Urban Sun' installation hopes to make public spaces safe again amid Covid-19
India records 18,327 new Covid-19 infections, active cases rise again
Drug used for treating arthritis could help lower risk of mortality from Covid: study
After TMC complaint, EC says remove PM’s photo from Covid jab certificate
Fresh Covid cases cross 10k in Maha, Delhi sees highest number in nearly 1.5 months
Dharavi is a Covid hotspot again, BMC on alert after 7x spike in cases
Govt: Over 13.8 lakh Covid-19 vaccines administered across India
Uber drives in support for vaccine drive, to provide free rides
Adar Poonawalla warns of vaccine delays due to US hurdles
UK will receive 10 mn doses of AstraZeneca Covid-19 vaccine from SII
Covid-19 vaccine mandatory for Hajj pilgrimage: Saudi govt